Amanta Healthcare shares extended gains after debuting at a 7% premium, reflecting moderate investor optimism despite steep valuations at 46.6x FY25 earnings. The sterile injectables maker plans to use IPO proceeds for capacity expansion under its SteriPort brand and SVP facility. Strong margins, growing exports, and branded generics support growth, though supply risks and competition remain overhangs.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets